Опухоли головы и шеи (Apr 2015)

CAPECITABINE IN THE TREATMENT OF BRAIN METASTATIC LESION IN PATIENTS WITH BREAST CANCER

  • E. A. Moskvina,
  • V. A. Gorbunova,
  • D. R. Naskhletashvili,
  • A. Kh. Bekyashev,
  • S. V. Medvedev,
  • S. B. Peterson

DOI
https://doi.org/10.17650/2222-1468-2012-0-3-59-62
Journal volume & issue
Vol. 0, no. 3
pp. 59 – 62

Abstract

Read online

The paper considers the experience with capecitabine in 67 patients with brain metastatic lesion from breast cancer. The immediate efficacy of capecitabine and the results of therapy with the agent were analyzed in the groups of its use alone and in combination with radiotherapy both for therapeutic purposes and as an adjuvant regimen. In the chemoradiation therapy group, the objective effects in the brain were 73 %. The median time to progression was 12.27 months. In the monochemotherapy group, the objective effects were 30 %. The median time to progression was 4 months. The results of the investigation show that capecitabine has pronounced antitumor activity and moderate toxicity. Combination treatment is the method of choice.

Keywords